Catalyst Database

10/10/23- Target enrollment reached. 6/4/24 Positive Ph3 data & webcast. 6/25/24 Presented additional positive Ph3 data at PNS '24. 8/12/24 Initial RWE topline data by YE 2024. BLA submission in H1 2025. 12/24- Ph3 data demonstrated robust, consistent benefit across multiple endpoints. 12/16/24- Announced topline RWE data.

12/5/23- Initiated enrollment. 3/17/25- Phase 2a biomarker study interim data & topline data readouts in Q2 2025 and Q3 2025, respectively.

HERIZON-GEA-01 trial. With Zymeworks. 10/16/23- Presentation at ESMO 2023. 9/16/24 New and Updated Ph2 data at ESMO. Topline Ph3 PFS data in Q2'25.

7/17/24- Received clearance for Ph1 study. 8/14/24 - First patient dosed. 10/17/24 First-in-Human Ph1 Study fully recruited & progress to dose escalation. 12/17/24- Reported initial safety data. PK/PD assessment data in H1 2025.

W/ Immunovant. Topline results from 2 Ph3 trials in H1 2025.

XmAb717-04 study. 2/27/24- Presented early clinical data from monotherapy. For both monotherapy and combo w/ chemo, continue enrollment, provide data update and decision on advancement by H1 2025. 2/27/25- Paused further development.

MD Anderson trial 2020-0123. 4/2/24- Completed Ph1 dose esc. and established RP2D. Dose expansion ongoing. 5/21/24- Presentation of first data H1 2025.

Collab w/ MD Anderson. 5/21/24- Dose escalation part completed and dose expansion part ongoing. 12/9/24- Completed Ph1 study. Present full results from completed dose esc & dose exp parts at a medical congress in H1 2025.

Data from combination trial in H1 2025.

Ph1/2 top-line data in Q2 2025.